Immunology and inflammation

News

Roche deepens ties with Jnana with a second licensing deal

Swiss pharma group Roche has doubled down on a partnership with Jnana Therapeutics, paying $50 million upfront to tap into the Boston-based biotech drug discovery platform for a wide-rangin

News

Galapagos' new CEO Paul Stoffels wields axe in bid to go 'fo...

When long-serving Johnson & Johnson R&D chief Paul Stoffels cut short his retirement to

News

Weak data for Fasenra undermine AZ's ambitions for the drug

AstraZeneca's IL-5 inhibitor Fasenra is already making blockbuster sales from its use in eosinophilic asthma, but the drugmaker's efforts to expand its label keep running into difficulties.

News

Novo Nordisk grabs NASH drug from Ventus in $703m deal

Denmark's Novo Nordisk has agreed to pay $70 million to license rights to a drug developed by Ventus Therapeutics with potential in non-alcoholic steatohepatitis (NASH) and several other di

News

Boehringer Ingelheim, Biberach, Germany, February 2007

Boehringer bags first approval for rare skin disease drug

German drugmaker Boehringer Ingelheim has its first regulatory approval for spesolimab, its antibody therapy for rare and life-threatening skin disorder generalised pustular psoriasis (GPP)

News

BMS adds to IBD pipeline with $1.9bn GentiBio deal

Bristol-Myers Squibb has formed an R&D partnership with GentiBio, aimed at developing regulatory T cel (Treg) therapies for inflammatory bowel disease (IBD).

Roche deepens ties with Jnana with a second licensing deal

Galapagos' new CEO Paul Stoffels wields axe in bid to go 'fo...

Weak data for Fasenra undermine AZ's ambitions for the drug

Novo Nordisk grabs NASH drug from Ventus in $703m deal

Boehringer bags first approval for rare skin disease drug

BMS adds to IBD pipeline with $1.9bn GentiBio deal

FDA cites 'significant concerns' with ADC lymphoma trial

Discover a new era of healthcare panel engagement: Grounded ...

Immunology and inflammation

Editor's Picks